AVBP Earnings History
ArriVent BioPharma, Inc. Common Stock (AVBP) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.35B, listed on NASDAQ, employing roughly 52 people, carrying a beta of 1.52 to the broader market. ArriVent BioPharma, Inc. Led by Zhengbin Yao, public since 2024-01-26.
ArriVent BioPharma, Inc. Common Stock has beat EPS estimates in 1 of the last 6 quarters.
| Date | EPS Est. | EPS Actual | Surprise | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 10, 2026 | -0.96 | N/A | N/A | N/A | N/A |
| May 11, 2026 | -0.88 | -0.96 | N/A | N/A | N/A |
| Mar 5, 2026 | -0.87 | -0.78 | N/A | N/A | N/A |
| Nov 10, 2025 | -0.78 | -0.83 | N/A | N/A | N/A |
| Aug 11, 2025 | -0.70 | -0.90 | N/A | N/A | N/A |
| May 12, 2025 | -0.66 | -1.90 | N/A | N/A | N/A |
What AVBP's Earnings History Tells Options Traders
ArriVent BioPharma, Inc. Common Stock has missed estimates more often than it has beat them (only 1 beats in 6 reports). Names with poor beat-rate history typically carry richer downside skew going into earnings and produce larger post-event moves on misses, conditions where put-spread or long-vol structures may carry edge over premium-selling. Beat rate is one input to event-driven sizing; pair it with the implied-vs-realized volatility view, the current IV rank, and the put-call skew going into the print. Surprise magnitude matters as much as direction - an in-line beat with conservative guidance can produce a larger negative move than a missed quarter with raised forward guidance. The earnings table above shows the most recent six reported quarters; for the full multi-year history including revenue growth trajectory and EPS guidance trends, the per-ticker fundamentals view aggregates the underlying GAAP filings.
How Earnings Drive AVBP Options Pricing
Earnings events are the largest single driver of single-name implied volatility in equity options markets. Pre-event, IV inflates over the two-to-three week run-up as the binary uncertainty of the print compounds; the IV rank typically peaks the day before the announcement. Post-event, IV crushes back toward the realized-volatility baseline as uncertainty resolves. The magnitude of the crush depends on how stretched pre-event IV was relative to the eventual realized move - an oversized pre-event IV with an undersized realized move produces the cleanest premium-selling outcome, while a stretched IV that still under-prices a tail move on the print produces the cleanest long-vol outcome.
The catalyst calendar for AVBP matters beyond the headline EPS surprise. Forward guidance revisions, capital-allocation changes (dividend hikes, buyback authorizations, M&A announcements), and segment-level performance discussions can drive larger post-event moves than the headline beat or miss. Pair the earnings beat-rate read above with the upcoming-event calendar and the IV-rank view to size pre-event and post-event positioning; for short-vol structures the goal is to be long premium-rich and to harvest the IV crush, while for long-vol structures the goal is to own gamma cheap into a regime where the realized move is likely to exceed the implied move.
Frequently asked AVBP earnings questions
- How often does AVBP beat earnings estimates?
- ArriVent BioPharma, Inc. Common Stock (AVBP) has beat consensus EPS estimates in 1 of the last 6 quarters. The table above shows estimate, actual, surprise percent, and revenue figures per quarter. Beat-rate matters less than the *pattern* of beats and misses: a name with a consistent beat history sees implied-vol expansion ahead of the print and a sharp IV crush after.
- What was AVBP's last reported earnings?
- The most recent reported quarter is Aug 10, 2026. Revenue, EPS, and prior-quarter comparisons are in the table above. Subsequent estimates and analyst-revisions live on the analyst-ratings page.
- How do AVBP earnings drive options pricing?
- Earnings events are the single largest driver of single-name implied volatility in equity options markets. Pre-event, IV inflates as the market prices the binary outcome (beat / miss / guidance change). Post-event, IV crushes as uncertainty resolves. The size of the crush is a function of how stretched pre-event IV was relative to the realized move: an oversized pre-event IV with an undersized move produces the cleanest premium-selling result. Pair AVBP earnings history with the implied-vs-realized volatility view to size pre-event positioning.
- When does AVBP report next?
- Next-quarter earnings dates are typically announced by the company 3-6 weeks ahead. Check the earnings-calendar page or company investor-relations site for the confirmed date. Pre-event IV typically begins building 2-3 weeks before the announcement and peaks the day before.